🇺🇸 FDA
Patent

US 11291667

Combination therapy involving diaryl macrocyclic compounds

granted A61KA61K31/506A61K31/517

Quick answer

US patent 11291667 (Combination therapy involving diaryl macrocyclic compounds) held by TURNING POINT THERAPEUTICS, INC. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TURNING POINT THERAPEUTICS, INC.
Grant date
Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/506, A61K31/517, A61K31/519, A61K31/5377